KInases: New horizons. Highlights from the Society of Medicines Research Symposium, held on October 3rd, 2013 - National Heart and Lung Institute, Kensington, London, UK

摘要

Of all the protein classes under investigation in the pharmaceutical industry, kinases represent one of the most well-worked (at least 20% of drug discovery research has been focused on kinase inhibitors for oncology) and successful (currently 13 small-molecule inhibitors have been approved by the FDA). Despite this, significant challenges and opportunities exist for both the exploitation of kinase inhibitors in new therapeutic areas and the development of novel technologies and methodologies to support their discovery and development. This meeting brought together experts in the field to review both areas. The first part of the meeting focuses on new technologies and strategies for the discovery of kinase inhibitors, including novel technologies and the exploitation of covalent and allosteric ligands. The second part of the meeting is dedicated to the discovery and development of kinase inhibitors for new and emerging therapeutic areas, in particular in CNS and tropical diseases.